Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary04/20/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/20/17 -- -- Novel genetic mutations predictive of response to AEVI-001 found in approximately 10% of pediatric ADHD patients -- -- New results clarify a path forward for the continued development of AEVI-001 in ADHD patients and potential future development
Toggle Summary04/12/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/12/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6 th World Congress on ADHD (Attention Deficit Hyperactivity
Toggle Summary03/30/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/30/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Brian D. Piper , Chief Financial Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m.
Toggle Summary03/20/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/20/17 -- Trial did not meet primary endpoint (overall ADHD-RS), however showed encouraging trend in improvement at highest dose (400 mg BID) Strong trend of efficacy in ADHD-RS inattention subscale (p=0.0515 vs placebo) Clear signal of efficacy and benefit to
Toggle Summary03/15/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference on Wednesday, March 22, 2017 at 3:20 p.m.
Toggle Summary03/09/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 Aevi
Toggle Summary02/27/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at
Toggle Summary02/21/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/21/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children's Hospital of
Toggle Summary02/15/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market.
Toggle Summary02/09/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at